2018
DOI: 10.1177/0961203318789766
|View full text |Cite
|
Sign up to set email alerts
|

Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus in a patient with progressive systemic sclerosis

Abstract: A 60-year-old female was diagnosed with progressive systemic sclerosis and interstitial lung disease of two months' duration. The patient was treated for Raynaud phenomenon with aspirin, nifedipine, colchicine, and naproxen. Two weeks after treatment, she developed widespread erythematous patches with blistering eruptions on the face, torso, and extremities, and also had erosion on the oral mucosa. Skin biopsy for histopathology and direct immunofluorescent studies were suggestive of lupus erythematosus. To th… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2019
2019
2019
2019

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 12 publications
0
1
0
Order By: Relevance
“…The strongest of HLA associations are HLA-B∗58:01 with allopurinol-induced hypersensitivity syndrome and SJS/TEN in Asian populations. [17] HLA-B∗58:01 in patients of all ethnicities administered with allopurinol are at high risk for SJS/TEN. Allopurinol, a xanthine oxidase inhibitor that blocks uric acid production, is used for the treatment of chronic gout, uric acid nephrolithiasis, and hyperuricemia secondary to tumor lysis syndrome.…”
Section: Discussionmentioning
confidence: 99%
“…The strongest of HLA associations are HLA-B∗58:01 with allopurinol-induced hypersensitivity syndrome and SJS/TEN in Asian populations. [17] HLA-B∗58:01 in patients of all ethnicities administered with allopurinol are at high risk for SJS/TEN. Allopurinol, a xanthine oxidase inhibitor that blocks uric acid production, is used for the treatment of chronic gout, uric acid nephrolithiasis, and hyperuricemia secondary to tumor lysis syndrome.…”
Section: Discussionmentioning
confidence: 99%